理洫王^(R)血塞通软胶囊临床应用专家共识  

Expert consensus on clinical application of Lixuwang Xuesaitong Soft Capsules

作　　者：贾敏[1] 梁晓 付国静 金香兰[2] 鲁喦[1] 廖星[3] 张允岭 代表编制组 JIA Min;LIANG Xiao;FU Guo-jing;JIN Xiang-lan;LU Yan;LIAO Xing;ZHANG Yun-ling;represented editorial team(Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China;Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;不详)

机构地区：[1]中国中医科学院西苑医院,北京100091 [2]北京中医药大学东方医院,北京100078 [3]中国中医科学院中医临床基础医学研究所,北京100700 [4]不详

出　　处：《中国中药杂志》2023年第20期5668-5674,共7页China Journal of Chinese Materia Medica

基　　金：国家中医药管理局中医药创新团队及人才支持计划项目(ZYYCXTD-C-202007);中国中医科学院科技创新工程项目(CI2021A05503,CI2021A00701-3,CI2021A01301);中医药防治脑病传承创新团队项目(CI2021B006);中央级公益性科研院所基本科研业务费专项(ZZ13-024-3);中国中医药循证医学中心业务研究室主任专项(2020YJSZX-2)。

摘　　要：理洫王^(R)血塞通软胶囊(简称“血塞通软胶囊”)具有活血祛瘀,通脉活络的功效,临床上广泛用于心脑血管疾病的预防和治疗。经多年临床观察,其对缺血性脑卒中、冠心病等有明显疗效,受到多个指南、共识及丛书的推荐。该文在总结临床医生应用经验的基础上,结合现有循证证据,遵照中华中医药学会标准化办公室《中成药临床专家共识研制技术规范》,通过名义组法共达成19条推荐意见/共识建议,提出了血塞通软胶囊治疗缺血性脑卒中和冠心病心绞痛的用药时机、辨证用药、治疗作用、用法用量、疗程、经济性考虑等,并说明了临床应用的安全性。该共识适用于各级医疗机构的内科、脑病科(神经内科)、心血管内科、老年病科、急诊科、全科、中医科的医师,以及医院和药店的药师在使用血塞通软胶囊时作为用药参考。希冀该共识的推广应用可以提高血塞通软胶囊治疗缺血性脑卒中和冠心病的临床疗效,促进合理用药,减少用药风险。该共识已通过中华中医药学会的审核,并进行了发布,编号GS/CACM 323-2023。Lixuwang Xuesaitong Soft Capsules(referred to as "Xuesaitong Soft Capsules") have the effects of promoting blood circulation,resolving blood stasis,and dredging meridians and collaterals.They are widely used in the prevention and treatment of cardiovascular and cerebrovascular diseases in clinical practice.Through years of clinical observation,they have shown significant efficacy in ischemic stroke,coronary heart disease,and other diseases,and have been recommended by multiple guidelines,consensus statements,and monographs.Based on the summary of clinical application experience by doctors and existing evidence-based research,following the Technical Specifications for Consensus Development of Chinese Patent Medicine by Clinical Experts issued by Standardization Office of the Chinese Association of Traditional Chinese Medicine,a nominal group method was used to reach 19 recommended opinions/consensus suggestions.This document proposes the timing of medication,syndrome differentiation for medication,therapeutic effects,dosage and administration,treatment duration,economic considerations,and safety considerations in the use of Xuesaitong Soft Capsules for the treatment of ischemic stroke and angina pectoris in coronary heart disease.It is intended for doctors in internal medicine,encephalopathy(neurology),cardiovascular medicine,geriatrics,emergency medicine,general practice,and traditional Chinese medicine departments of various medical institutions,as well as pharmacists in hospitals and pharmacies,as a medication reference when using Xuesaitong Soft Capsules.It is hoped that the widespread application of this consensus can improve the clinical efficacy of Xuesaitong Soft Capsules in the treatment of ischemic stroke and coronary heart disease,promote rational drug use,and reduce medication risks.This consensus has been reviewed and published by the China Association of Traditional Chinese Medicine,with the identification number GS/CACM 323-2023.

关 键 词：血塞通软胶囊 缺血性脑卒中 冠心病心绞痛 专家共识 中成药 

分 类 号：R286[医药卫生—中药学]